How Does Vertex Pharmaceuticals Make its Money?
Vertex Pharmaceuticals is a biotechnology company that has built a near-monopoly in the treatment of cystic fibrosis (CF), a rare genetic disease. Its CF franchise — led by the blockbuster combination therapy Trikafta — treats approximately 90% of eligible CF patients and generates the vast majority of Vertex’s revenue. The company is now diversifying into pain (suzetrigine, a non-opioid painkiller), kidney disease, gene editing (through its CRISPR partnership Casgevy for sickle cell disease), and other areas to build its next growth chapter beyond CF.
Vertex Pharmaceuticals (VRTX) Business Model
Vertex Pharmaceuticals operates in the biotechnology sector. Below is a summary of Vertex Pharmaceuticals’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Vertex Pharmaceuticals’ 2024 fiscal year filings with the SEC.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Vertex Pharmaceuticals Competitors
Vertex Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Vertex Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Trikafta/Kaftrio (cystic fibrosis) | $9,200 | $8,600 | +7.0% |
| Other CF Products (Orkambi, Symdeko, Kalydeco) | $700 | $800 | -12.5% |
| Casgevy (sickle cell / beta-thalassemia) | $200 | $0 | N/A |
| Other Revenue | $500 | $300 | +66.7% |
| Total Revenue | $10,800 | $9,900 | +9.1% |
Trikafta/Kaftrio (cystic fibrosis) — 85% of Revenue
Other CF Products (Orkambi, Symdeko, Kalydeco) — 6% of Revenue
Casgevy (sickle cell / beta-thalassemia) — 2% of Revenue
Other Revenue — 5% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $10,800 | $9,900 |
| Cost of Revenue | $1,100 | $1,000 |
| Gross Profit | $9,700 | $8,900 |
| Operating Expenses | $4,800 | $4,200 |
| Operating Income | $4,900 | $4,700 |
| Net Income | $4,000 | $3,600 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 89.8%
- Operating Margin: 45.4%
- Revenue Growth: 9.1%
Is Vertex Pharmaceuticals Profitable?
Yes, Vertex Pharmaceuticals is profitable. The company reported net income of $4,000 on total revenue of $10,800. With an operating margin of 45.4%, Vertex Pharmaceuticals demonstrates solid profitability for the biotechnology sector. The gross margin of 89.8% reflects Vertex Pharmaceuticals’ pricing power and cost structure.
What to Watch
- Suzetrigine (non-opioid pain drug) FDA approval and commercial launch potential
- Trikafta CF patient penetration in international markets
- Casgevy adoption for sickle cell disease and manufacturing scale-up
- Pipeline diversification into kidney disease (VX-147) and type 1 diabetes
Vertex Pharmaceuticals (VRTX) Financial Summary
Vertex Pharmaceuticals (VRTX) is a biotechnology company that generated $10,800 in total revenue in fiscal year 2024. Revenue grew 9.1% year-over-year. The company earned $4,000 in net income, making it profitable. For a deeper look at Vertex Pharmaceuticals’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.